Clinical implication of targeting of cancer stem cells

European Surgical Research

Volumn 49, Issue 1, 2012, Pages 8-15

  Zhao, L ^a   Zhao, Y ^a   Bao, Q ^a   Niess, H ^a   Jauch, K W ^a   Bruns, C J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cancer stem cells; Molecular markers; Resistance; Signaling pathway; Target therapy

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXY 1 METHYLTETRALIN; BCR ABL PROTEIN; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CATHEPSIN B; CATHEPSIN L; CYSTEINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLYCOPROTEIN P; IMATINIB; IRINOTECAN; MICRORNA 124; MICRORNA 200; MULTIDRUG RESISTANCE PROTEIN 1; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SONIC HEDGEHOG PROTEIN; TEMOZOLOMIDE; VASCULOTROPIN; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STEM CELL; CANCER SURGERY; CARCINOGENICITY; CELL DIFFERENTIATION; CELL DISRUPTION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; ENDOTHELIAL PROGENITOR CELL; EVENT FREE SURVIVAL; GLIOBLASTOMA; GLIOMA; HEMATOPOIETIC CELL; HUMAN; IN VIVO STUDY; LONG TERM CARE; MOLECULARLY TARGETED THERAPY; NEUROEPITHELIUM; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR BURDEN;

EID: 84863755025     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000339610     Document Type: Review

References (78)

1. Gilbert CA, Ross AH: Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem 2009; 108: 1031-1038.
2. Eyler CE, Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-2845.
3. Ghiaur G, et al: Cancer stem cells: relevance to clinical transpla ntation. Curr Opin Oncol 2012; 24: 170-175.
4. Dou J, Gu N: Emerging strategies for the identification and targeting of cancer stem cells. Tumour Biol 2010; 31: 243-253.
5. Vermeulen L, et al: The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012; 13:e83-e89.
6. O'Brien SG, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
7. Kiladjian JJ, Mesa RA, Hoffman R: The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117: 4706-4715.
8. Hochhaus A, et al: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
9. Cortes J, O'Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-2205.
10. Mauro MJ, Druker BJ, Maziarz RT: Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28(suppl 1):S71-S73.
11. Merante S, et al: Outcome of four patients with chronic myeloid leukemia after ima-tinib mesylate discontinuation. Haemato-logica 2005; 90: 979-981.
12. Jones RJ, Matsui W: Cancer stem cells: from bench to bedside. Biol Blood Marrow Transplant 2007; 13(suppl 1):47-52.
13. Jones RJ, Matsui WH, Smith BD: Cancer stem cells: are we missing the target? J Natl Cancer Inst 2004; 96: 583-585.
14. Huff CA, et al: The paradox of response and survival in cancer therapeutics. Blood 2006; 107: 431-434.
15. Jones RJ: Cancer stem cells-clinical relevance. J Mol Med (Berl) 2009; 87: 1105-1110.
16. Rasheed ZA, et al: Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011; 29: 883-887.
17. Garvalov BK, Acker T: Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med (Berl) 2011; 89: 95-107.
18. Park CY, Tseng D, Weissman IL: Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2009; 17: 219-230.
19. Costello R, et al: The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38-leuke-mic progenitors. Leukemia 1999; 13: 1513-1518.
20. Haferlach T, et al: Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003; 21: 256-265.
21. Strojnik T, et al: Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 2007; 68: 133-143, discussion 143-144.
22. Tu LC, et al: Targeting stem cells-clinical implications for cancer therapy. Curr Stem Cell Res Ther 2009; 4: 147-153.
23. Klonisch T, et al: Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med 2008; 14: 450-460.
24. Liu R, et al: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226.
25. Tang C, Ang BT, Pervaiz S: Cancer stem cell: target for anti-cancer therapy. FASEB J 2007; 21: 3777-3785.
26. Liu G, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
27. Wright MH, et al: Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10:R10.
28. Richardson GD, et al: CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539-3545.
29. Collins AT, et al: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
30. Tang M, et al: Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 2011; 118: 1622-1631.
31. Roeder I, et al: Dynamic modeling of ima-tinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181-1184.
32. Bardsley MR, et al: Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010; 139: 942-952.
33. Dylla SJ, et al: Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3:e2428.
34. Todaro M, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
35. Wilson BJ, et al: ABCB5 identifies a therapy-refractory tumor cell population in colorec-tal cancer patients. Cancer Res 2011; 71: 5307-5316.
36. Szotek PP, et al: Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-11159.
37. Moserle L, et al: Side population and cancer stem cells: therapeutic implications. Cancer Lett 2010; 288: 1-9.
38. Fischer S, et al: Identification of multi-drug resistance associated proteins MRP1 (ABCC1) and MRP3 (ABCC3) from rainbow trout (Oncorhynchus mykiss). Mar Environ Res 2010; 69(suppl):S7-S10.
39. Bruns CJ, et al: In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999; 1: 50-62.
40. Bao S, et al: Glioma stem cells promote radio-resistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
41. Phillips TM, McBride WH, Pajonk F: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
42. Diehn M, et al: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
43. Chen MS, et al: Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007; 120: 468-477.
44. Blazek ER, Foutch JL, Maki G: Daoy medul-loblastoma cells that express CD133 are ra-dioresista nt relative to CD133-cells, and t he CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007; 67: 1-5.
45. Platet N, et al: Inf luence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007; 258: 286-290.
46. Bentzen SM: Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005; 6: 112-117.
47. Stupp R, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
48. Mimeault M, et al: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007; 11: 981-1011.
49. Hosen N, et al: CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 2007; 104: 11008-11013.
50. Kojima T, Kitamura T: A signal sequence trap based on a constitutively active cytokine receptor. Nat Biotechnol 1999; 17: 487-490.
51. Lonardo E, et al: Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433-446.
52. Zhou BB, et al: Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-823.
53. Reya T, et al: Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
54. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850.
55. Jiang X, et al: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926-935.
56. Zhao C, et al: Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009; 458: 776-779.
57. Kanamori M, et al: Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 2007; 106: 417-427.
58. Jayasekera BA, Bacon AD, Whitfield PC: Management of glioblastoma multiforme in pregnancy. J Neurosurg 2012, E-pub ahead of print.
59. Ju Z, Rudolph KL: Telomeres and telomerase in cancer stem cells. Eur J Cancer 2006; 42: 1197-1203.
60. Brunsvig PF, et al: Telomerase peptide vaccination in NSCLC: a phase II trial in stage 111 patients vaccinated after chemoradio-therapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17: 6847-6857.
61. Hurwitz H, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
62. 2 availability on human cancer. Nat Rev Cancer 2008; 8: 967-975.
63. Seidel S, et al: A hypoxic niche regulates glio-blastoma stem cells through hypoxia induc-ible factor 2 alpha. Brain 2010; 133: 983-995.
64. Korpal M, et al: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008. 283: 14910-14914.
65. Liu S, Clouthier SG, Wicha MS: Role of mi-croRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia 2012; 17: 15-21.
66. Cao X, Pfaff SL, Gage FH: A functional study of miR-124 in the developing neural tube. Genes Dev 2007; 21: 531-536.
67. Suh MR, et al: Human embryonic stem cells express a unique set of microRNAs. Dev Biol 2004; 270: 488-498.
68. Xu N, et al: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137: 647-658.
69. Singh A, Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
70. McDermott SP, Wicha MS: Targeting breast cancer stem cells. Mol Oncol 2010; 4: 404-419.
71. Barlogie B, et al: Completion of premainte-nance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. Cancer 2008; 112: 2720-2725.
72. Li C, et al: Identif icat ion of pa ncreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
73. Al-Hajj M, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
74. Dalerba P, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-10163.
75. Clayton S, Mousa SA: Therapeutics formulated to target cancer stem cells: is it in our future? Cancer Cell Int 2011; 11: 7.
76. Gibbs CP, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005; 7: 967-976.
77. Yu F, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123.
78. Singh SK, et al: REST maintains self-renewal and pluripotency of embryonic stem cells. Nature 2008; 453: 223-227.